Reach Us +44-1235425476
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Epigenetic Regulation of HSD11B2 Gene by Promoter Methylation in Glucocorticoid-Treated Patients

Background: A reduced activity of the 11 beta-hydroxysteroid dehydrogenase 2 (11 beta-HSD2) causes hypertension by conferring aldosterone selectivity to mineralcorticoid receptors and eventually impairing the tetrahydrocortisol-versus tetrahydrocortisone-metabolites (THFs/THE) shuttle. The 11 beta-HSD2 function is modulated by glucocorticoid treatment that may induce hypertension through a mechanism mostly unknown. Promoter methylation, one of the main epigenetic and potentially modifiable feature of DNA, regulates HSD11B2 gene expression and relates to the development of arterial hypertension.

Objective: To explore the mechanism by which steroid therapy influences blood pressure we investigated the effect of glucocorticoid-treatment on HSD11B2 promoter methylation and THFs/THE ratio, that reflects the 11 beta-HSD2 activity.

Method: We determined urinary THFs/THE ratio by gas chromatography/mass spectrometry and HSD11B2 methylation in promoter Region 1 and 2 using bisulfitepyrosequencing in DNA from peripheral blood mononuclear cells (PBMCs) of six normotensive subjects affected by autoimmune diseases at three time points: T0) baseline, T1) following one-month prednisone therapy (0.5-1 mg/kg daily), and T2) at least one year after withdrawal.

Results: Glucocorticoid treatment was associated with the increase of HSD11B2 promoter methylation, that was significant for Region 1 (T0 2.4%, T1 2.8%, P=0.046), and the concomitant raise of THFs/THE ratio (T0 1.29 ± 0.80, T1 4.10 ± 1.62, P=0.043). After glucocorticoid-withdrawal (T2) both parameters decreased (methylation 1.9%; THFs/THE ratio 1.09), although not significantly. A significant positive correlation was observed between HSD11B2 promoter methylation and the THFs/THE ratio.

Conclusion: High-dosage prednisone therapy alters promoter methylation of HSD11B2 and 11beta-HSD2 activity, influencing blood pressure: this effect appears slightly reversible after glucocorticoid-withdrawal, suggesting a dynamic epigenetic regulation of HSD11B2.


Author(s):

Simonetta Friso, Francesca Pizzolo, Silvia Udali, Patrizia Guarini, Annalisa Castagna, Letizia Consoli, Gianluca Salvagno, Elisa Tinazzi, Patrizia Pattini, Sang-Woon Choi, Claudio Lunardi and Oliviero Olivieri



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
Flyer image

Abstracted/Indexed in

  • Google Scholar
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs